问题 › 我们应该提高价格吗？ › 医疗服务提供商
问题从来不在于是否普遍调整基于价值合同的条款。而是哪些归属人次、每集调整多少，以及预计会导致的面板规模或合同损失。 对医疗服务提供商而言，这体现在特定位置。承载答案的数字是每集成本和支付方组合，而本行业特有的复杂之处在于，已在38,000人次上接受下行风险，却缺乏定价所需的每集成本数据。一般版本的问题与你实际面对的问题，首步动作不同。
问题从来不在于是否普遍调整基于价值合同的条款。而是哪些归属人次、每集调整多少，以及预计会导致的面板规模或合同损失。 对医疗服务提供商而言，这体现在特定位置。承载答案的数字是每集成本和支付方组合，而本行业特有的复杂之处在于，已在38,000人次上接受下行风险，却缺乏定价所需的每集成本数据。一般版本的问题与你实际面对的问题，首步动作不同。
归属人次的合同条款是此情境下最快的杠杆——无需新增人次、无需增加提供商、无需新服务线，且在下一结算周期即可见效。这也是运营者最不愿触碰的点，因此在38,000人次上留下下行风险却缺乏每集成本数据的合同仍会继续存在。
有用的分析不会只产出一个数字。它会按支付方组合和面板进行细分：哪些归属人次的每集成本低于合同价值，哪些已达到合同能承受的上限，以及提供商间贡献差异显示条款是由个别谈判而非政策决定。
不舒服的地方在于，好的调整会故意失去部分归属人次或合同。如果调整没有让你失去任何，说明条款相对于每集成本仍然过低。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 几乎所有基于价值的合同首次提交即被接受
✓ 提供商贡献在相同支付方组合下出现大范围无法解释的差异
✓ 每集成本已上升，而附着在38,000归属人次上的条款保持不变
通常会让情况更糟的做法。 对全部38,000归属人次进行统一条款调整，这会让支付方组合中的某些细分定价过高，同时仍让驱动最高每集成本的集数定价过低。
It is for you if you run or finance a healthcare provider and almost every deal closes, and closes quickly. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Pricing & Revenue Optimization, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
没有通用答案，有用的分析按细分进行。能说的是，你担心的流失通常集中在你会因失去他们而改善经济的群体。
先从新客户开始更安全也更慢；现有客户才是钱所在。合理的顺序是先调整新客户定价，观察一个季度的成交率，然后在续约时通知现有客户上调。
那你就是在用价格以外的东西与他们竞争，或者你没有——这才是真正的问题。在没有支撑成本结构的情况下靠价格竞争，是以越来越大的量亏损的最可靠方式。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית